CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: Further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma

Modern Pathology

Volumn 29, Issue 10, 2016, Pages 1254-1261

  Kuhn, Elisabetta ^a,e   Wang, Tian Li ^a   Doberstein, Kai ^b   Bahadirli Talbott, Asli ^a   Ayhan, Ayse ^a,c   Sehdev, Ann Smith ^d   Drapkin, Ronny ^b   Kurman, Robert J ^a,e   Shih, Ie Ming ^a,e  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Seirei Mikatahara Hospital   (Japan)

^d Legacy Health Systems   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN E; CYCLIN E1; UNCLASSIFIED DRUG; CCNE1 PROTEIN, HUMAN; ONCOPROTEIN;

ARTICLE; CANCER GRADING; CANCER PATIENT; CENTROSOME; CHROMOSOMAL INSTABILITY; CONTROLLED STUDY; CYSTADENOCARCINOMA; EPITHELIUM CELL; FALLOPIAN TUBE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; OVARIAN HIGH GRADE SEROUS CARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; SEROUS TUBAL INTRAEPITHELIAL CARCINOMA; TISSUE SECTION; TUMOR GROWTH; UTERINE TUBE CARCINOMA; CARCINOMA IN SITU; GENETICS; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; UTERINE TUBE TUMOR;

CARCINOMA IN SITU; CENTROSOME; CYCLIN E; CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENE AMPLIFICATION; HUMANS; MIDDLE AGED; NEOPLASM GRADING; ONCOGENE PROTEINS; OVARIAN NEOPLASMS;

EID: 84979207740     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2016.101     Document Type: Article

References (39)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
2. Kurman RJ, Shih IM. The dualistic model of ovarian carcinogenesis. revisited, revised and expanded. Am J Pathol 2016;186:733-747.
3. Crum CP, Drapkin R, Miron et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007;19:3-9.
4. Perets R, Wyant GA, Muto KW et al. Transformation of the fallopian tube secretory epithelium leads to highgrade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 2013;24:751-765.
5. Visvanathan K, Vang R, Shaw P et al. Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study. Am J Surg Pathol 2011;35: 1766-1775.
6. Kuhn E, Kurman RJ, Soslow RA et al. The diagnostic and biological implications of laminin expression in serous tubal intraepithelial carcinoma. Am J Surg Pathol 2012;36:1826-1834.
7. Karst AM, Levanon K, Duraisamy S et al. Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol Oncol 2011;123:5-12.
8. Novak M, Lester J, Karst AM et al. Stathmin 1 and p16 (INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma. Gynecol Oncol 2015; 139:104-111.
9. Kindelberger DW, Lee Y, Miron et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007;31:161-169.
10. Przybycin CG, Kurman RJ, Ronnett BM et al. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 2010;34:1407-1416.
11. Morrison JC, Blanco LZ Jr., Vang R et al. Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series. Am J Surg Pathol 2015;39: 442-453.
12. Gilks CB, Irving J, Kobel M et al. Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas. Am J Surg Pathol 2015;39:357-364.
13. Hirst JE, Gard GB, McIllroy K et al. High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy. Int J Gynecol Cancer 2009;19:826-829.
14. Rabban JT, Garg K, Crawford B et al. Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery. Am J Surg Pathol 2014;38:729-742.
15. Tang S, Onuma K, Deb P et al. Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies: a study of 300 consecutive cases. Int J Gynecol Pathol2012;31:103-110.
16. Kuhn E, Kurman RJ, Vang R et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol 2012;226:421-426.
17. Kuhn E, Meeker A, Wang TL et al. Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. Am J Surg Pathol 2010;34:829-836.
18. Sherman-Baust CA, Kuhn E, Valle BL et al. A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. J Pathol 2014;233:228-237.
19. Kobayashi Y, Kashima H, Wu RC et al. Mevalonate pathway antagonist inhibits proliferation of serous tubal intraepithelial carcinoma and ovarian carcinoma in mouse models. Clin Cancer Res 2015;21:4625-4662.
20. McDaniel AS, Stall JN, Hovelson DH et al. Nextgeneration sequencing of tubal intraepithelial carcinomas. JAMA Oncol 2015;1:1128-1132.
21. Fukasawa K. Centrosome amplification, chromosome instability and cancer development. Cancer Lett 2005;230:6-19.
22. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474:609-615.
23. Patch AM, Christie EL, Etemadmoghadam D et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 2015;521:489-494.
24. Etemadmoghadam D, George J, Cowin PA et al. Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PLoS One 2010;5:e15498.
25. Nakayama K, Nakayama N, Jinawath N et al. Amplicon profiles in ovarian serous carcinomas. Int J Cancer 2007;120:2613-2617.
26. Sehdev AS, Kurman RJ, Kuhn E et al. Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. Mod Pathol 2010;23:844-855.
27. Karst AM, Jones PM, Vena N et al. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res 2014;74:1141-1152.
28. Farley J, Smith LM, Darcy KM et al. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. Cancer Res 2003;63:1235-1241.
29. Rosen DG, Yang G, Deavers MT et al. Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer 2006;106:1925-1932.
30. Davidson B, Skrede M, Silins I et al. Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer 2007;110:1264-1271.
31. Nigg EA, Stearns T. The centrosome cycle: centriole biogenesis, duplication and inherent asymmetries. Nat Cell Biol 2011;13:1154-1160.
32. Cope L, Wu RC, Shih Ie M et al. High level of chromosomal aberration in ovarian cancer genome correlates with poor clinical outcome. Gynecol Oncol 2013;128:500-505.
33. Kuhn E, Bahadirli-Talbott A, Shih Ie M. Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma. Mod Pathol 2014;27:1014-1019.
34. Kuhn E, Ayhan A, Shih Ie M et al. Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. Eur J Cancer 2013;49:3839-3849.
35. Sheu JJ, Choi JH, Guan B et al. Rsf-1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development. J Pathol 2013;229: 559-568.
36. Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature 1999;401: 297-300.
37. Bagheri-Yarmand R, Biernacka A, Hunt KK et al. Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. Cancer Res 2010;70: 5074-5084.
38. Chui MH, Wang Y, Wu RC et al. Loss of ALDH1A1 expression is an early event in the pathogenesis of ovarian high-grade serous carcinoma. Mod Pathol 2015;28:437-445.
39. Loncarek J, Khodjakov A. Ab ovo or de novo? Mechanisms of centriole duplication. Mol Cells 2009; 27:135-142.